A Multi-center Prospective Cohort Study Based on Peritoneal Dialysis Telemedicine-assisted Platform
Launched by PEKING UNIVERSITY FIRST HOSPITAL · Jun 22, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a new telemedicine platform can help patients who are on peritoneal dialysis, a treatment for those with severe kidney disease. The goal is to create a database that tracks patient outcomes, such as survival rates and the effectiveness of the treatment, to better understand how to improve care for these patients. By using this technology, researchers hope to make it easier for patients to manage their treatment and identify any factors that might affect their health.
To participate in this study, individuals need to be at least 14 years old and currently receiving peritoneal dialysis for end-stage renal disease. However, those who are on temporary dialysis due to a sudden kidney problem or who do not follow up with their treatment will not be eligible. Participants can expect to be part of a team that collects important health information, which could help improve future care for others in similar situations. This study is currently recruiting participants, and anyone interested should consider discussing it with their healthcare provider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • End-stage renal disease patients receiving maintenance peritoneal dialysis;
- • more than 14 years old
- Exclusion Criteria:
- • receiving temporary PD due to acute kidney injury
- • loss to follow up without any outcomes recorded.
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Shijiazhuang, Hebei, China
Shijiazhuang, Hebei, China
Beijing, , China
Changchun, Jilin, China
Beijing, Beijing, China
Harbin, Heilongjiang, China
Zhengzhou, Henan, China
Cangzhou, Hebei, China
Taiyuan, Shanxi, China
Beijing, , China
Hefei, Anhui, China
Taiyuan, Shanxi, China
Shenzhen, Guangdong, China
Pingdingshan, Henan, China
Chuxiong, Yunnan, China
Lanzhou, Gansu, China
Cangzhou, Hebei, China
Handan, Hebei, China
Langfang, Hebei, China
Baotou, Inner Mongolia, China
Liaoyang, Liaoning, China
Xining, Qinghai, China
Xining, Qinghai, China
Beijing, , China
Beijing, , China
Beijing, , China
Chongqing, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials